Targeting mitotic exit has been recently proposed as a relevant therapeutic approach against cancer. By using genetically engineered mice, we show that the APC/C cofactor Cdc20 is essential for anaphase onset in vivo in embryonic or adult cells, including progenitor/stem cells. Ablation of Cdc20 results in efficient regression of aggressive tumors, whereas current mitotic drugs display limited effects. Yet, Cdc20 null cells can exit from mitosis upon inactivation of Cdk1 and the kinase Mastl (Greatwall). This mitotic exit depends on the activity of PP2A phosphatase complexes containing B55a or B55d regulatory subunits. These data illustrate the relevance of critical players of mitotic exit in mammals and their implications in the balance between cell death and mitotic exit in tumor cells.
INTRODUCTION
Multiple efforts in the last two decades have been put toward the evaluation of therapeutic advantages of cell cycle inhibition in tumor cells (Malumbres and Barbacid, 2009 ). These strategies include impairing the entry into the cell cycle by inhibition of cyclin-dependent kinases (Cdks), arresting cells at the G1/S or G2/M transitions with DNA-damaging agents, or inhibiting mitotic progression by targeting microtubules or mitotic kinases (Jackson and Bartek, 2009; Jordan and Wilson, 2004; Barbacid, 2001, 2007) . In most cases, tumor proliferation is only transiently or partially reduced. For instance, inhibiting G1 Cdks only results in minor defects given the compensation between multiple family members, and G0/G1-arrested cells can resume cell cycle proliferation upon activation of the appropriate stimuli (Malumbres and Barbacid, 2009 ). Checkpoint-mediated arrest can be transient once the insulting conditions have been eliminated or repaired or as a result of adaptation to the checkpoints (Syljuasen, 2007; Weaver and Cleveland, 2005) . In addition, resistance to microtubule poisons can be acquired by expression of particular tubulin isoforms or microtubule-regulating proteins (Kavallaris, 2010) , and cells can display many variable fates following exposure to microtubule drugs (Gascoigne and Taylor, 2008) .
More recently, mitotic exit has been proposed as a relevant target given the proapoptotic effect of RNA interference (RNAi) against the anaphase-promoting complex/cyclosome (APC/C) cofactor Cdc20 (Huang et al., 2009) . Chromosome segregation requires the activity of the APC/C, an E3 ubiquitin ligase that targets critical cell cycle regulators for degradation (Peters, 2006; Sullivan and Morgan, 2007) . APC/C recognizes its substrates through two adaptor proteins, Cdc20 and Cdh1. Cdc20 is responsible for APC/C function during the early phases of mitosis and for triggering mitotic exit at the metaphase-toanaphase transition. Cdh1 activates the APC/C during the final phases of mitosis and G1 (Peters, 2006) . The current model states that, upon complete bipolar attachment of all chromosomes to spindle microtubules, the activation of APC/C by Cdc20 results in the elimination of two critical targets: securin, a separase inhibitor; and cyclin B, the activating subunit of Significance Despite the multiple efforts to inhibit the cell cycle in tumors, most therapeutic approaches are limited due to compensatory effects or by adaptation to the therapeutic conditions. We show in this manuscript that mammalian cells require Cdc20 for anaphase onset in vivo. Genetic ablation of Cdc20 results in dramatic tumor regression due to apoptotic cell death, whereas parallel treatments with current mitotic drugs display more limited effects. Inhibition of the kinases Cdk1 and Mastl mediates a PP2A-B55-dependent mitotic exit and protection from apoptosis in Cdc20-depleted cells. Full understanding of this pathway is likely to be critical for improving strategies aimed to target mitotic exit for cancer treatment.
Cdk1. This results in the subsequent inhibition of Cdk1 and activation of separase, a protease that cleaves cohesion complexes that maintain sister chromatids together (Peters, 2006; Sullivan and Morgan, 2007) . In yeast, inhibition of Cdk1 and separase activity also results in the activation of Cdc14 phosphatases that remove mitotic phosphates, thus triggering mitotic exit (Stegmeier and Amon, 2004; Sullivan and Morgan, 2007) . The overall mechanism is thought to be conserved in vertebrates, although the relevance of the different molecular pathways involved is not clear. First, strong RNAi against Cdc20 or the APC/C catalytic subunit Apc2 has failed to induce mitotic arrest in some studies (Baumgarten et al., 2009; Gimenez-Abian et al., 2005) , probably as a consequence of residual Cdc20 activity (Wolthuis et al., 2008) . Second, inhibition of Cdk1-cyclin B may be insufficient for mitotic exit in the presence of proteasome inhibitors, and a new mechanism involving proteasome-dependent degradation of phosphatase inhibitors has been proposed (Skoufias et al., 2007) . Finally, vertebrate Cdc14 phosphatases do not seem to play a critical role in mitotic exit (Queralt and Uhlmann, 2008) , and PP1 or PP2A may function as mitotic exit phosphatases, at least in Xenopus Vigneron et al., 2009; Wu et al., 2009) . In this manuscript we investigate the requirements for mitotic exit in mammals and their implication in cancer therapy by using a conditional mutation in the murine Cdc20 gene.
RESULTS

Genetic Ablation of Cdc20 Results in Metaphase Arrest In Vivo
The conditional null mutation in the mouse Cdc20 gene was generated by homologous recombination in ES cells (see Fig- ure S1 available online). Cdc20(+/À) mice are viable and fertile. As previously shown using a gene-trap allele (Li et al., 2007) , lack of Cdc20 results in embryonic lethality at the two-cell stage ( Figures 1A and 1B ). These cells arrest in metaphase by E1.5 and display abnormal mitotic figures during the following days, probably as a consequence of prolonged metaphase arrest. For conditional ablation in vivo, we made use of a conditional allele (Cdc20(lox)) in which exon 2 is flanked by loxP sites ( Figure S1 ). In these animals a tamoxifen-inducible form of the Cre recombinase (Cre-ERT2) (Guerra et al., 2003) is expressed from the 3 0 -UTR of the RNA polymerase II gene (RERT allele). Pregnant females were treated at E10.5 ( Figure 1C ) or E12.5 ( Figure S2 ) with 4-hydroxytamoxifen (4-OHT) to induce Cre activity and excision of exon 2 (Cdc20(D) allele). Cdc20(À/D); RERT(+/Cre) embryos that inherit a Cdc20(À) null allele and a Cdc20(lox) allele display a dramatic arrest in development 24 hr after activation of the Cre recombinase with 4-OHT. A detailed histological analysis of these samples reveals a general proliferative arrest characterized by the presence of abundant metaphase figures and high levels of cyclin B in all proliferating tissues ( Figure 1C ; Figure S2 ).
To further investigate whether Cdc20 is also required at postembryonic stages, we fed 1 month old Cdc20(À/lox); RERT (+/Cre) mice and control littermates carrying a Cdc20(+) wildtype allele or lacking Cre with a 4-OHT supplemented diet. This treatment does not significantly modify the viability of control mice. However, all Cdc20(À/D); RERT(+/Cre) mice die after 8-10 days on the 4-OHT diet (Figure 2A ). This death is likely to be associated with the dramatic loss of weight in Cdc20(À/D); RERT(+/Cre) mice, but not in the Cdc20(+/D); RERT(+/Cre), Cdc20(+/lox); RERT(+/+), or Cdc20(À/lox); RERT(+/+) control groups ( Figure 2B ). Figure S2 ), and embryos were extracted 24 hr later. In control (Cdc20(+/D); RERT2(+/Cre)) samples, most cells are interphasic or display anaphase figures (insets), as observed in the proliferating neuroepithelium. Cdc20-deficient embryos display a dramatic accumulation of cells in metaphase. Some of these metaphases are positive for BrdU after a 6 hr pulse with this marker. However, most metaphase cells are negative for BrdU, indicating that they have been arrested in metaphase during longer periods. Cdc20 null cells also display a dramatic accumulation of cyclin B1 after specific immunostaining. Scale bars, 20 mM (H&E) or 10 mM (immunohistochemistry).
proliferative areas in diverse tissues such as intestine and testis display abundant mitotic figures representative of metaphases, suggesting that the lack of Cdc20 causes widespread metaphase arrest in proliferating cells in vivo (Figures 2C and 2D ; Figure S2 ). The phenotype induced by Cdc20 loss in intestinal epithelium suggests that Cdc20(À/D); RERT(+/Cre) mice die because of impaired absorption of nutrients. Genetic ablation of Cdc20 in older (1 year old) mice results in similar cellular defects in proliferating cells. However, these treated mice display improved survival. Two out of eight older mice can survive for several months despite the absence of Cdc20 expression, suggesting that these mice are less susceptible to the physiological consequences of loss of proliferation ( Figure 2E) . Figure 3A ). To induce proliferation of progenitor cells and hair regeneration, mice were depilated 8 days after a single 4-OHT application. Following this treatment, abundant metaphase figures are observed in multiple cells in the hair follicles, including CD34-positive progenitor cells. This hair regeneration response is impaired in Cdc20(À/D); RERT(+/Cre) mice without the need of further 4-OHT applications ( Figure 3A ). These data suggest that elimination of Cdc20 in nonproliferating cells is silent during quiescence or interphase; however, metaphase arrest is observed once these cells are committed to cell division. Similar ablation of Cdc20 in hematopoietic progenitor/stem cells also results in metaphase arrest and complete impairment in the formation of colonies ex vivo ( Figures 3B  and 3C ). In most cases these tumors acquire a whitish appearance, dry, and fall off and are no longer observed in the skin of these treated mice ( Figure 4C ). Histological observation of treated tumor samples indicates that lack of Cdc20 results in a massive arrest of tumor cells in metaphase-like stages. These tumor samples also contain abundant apoptotic figures ( Figure 4D ) that are not frequently observed in normal Cdc20-deficient epithelial tissues.
Since these skin tumors are relatively benign, we also analyzed aggressive fibrosarcomas induced by Cdc20(lox/lox); RERT(+/Cre) fibroblasts expressing H-ras V12 and E1A, two oncogenes that disrupt major tumor suppressor pathways, such as the retinoblastoma protein route in human tumors. Primary mouse embryonic fibroblasts (MEFs) were transfected with RasV12 and E1A-expressing vectors, and transformed foci were used to generate stable clones. Application of 1 mM Figure 5G ). We have also tested whether apoptotic cell death in Cdc20-deficient cells is mediated by p53 by using Cdc20(lox/lox); p53(À/À) double-mutant MEFs. In these cells the apoptotic cell death induced by Cdc20 ablation is not prevented by p53 deletion ( Figure S3 ). Overall, these results indicate that Cdc20-directed therapies may be efficient in most tumor types, regardless of their alteration in Ras, pRb, or p53 routes, three of the most frequently mutated pathways in human cancer. 
Efficient Mitotic Arrest and Apoptosis in the Absence of Cdc20
Multiple mitotic drugs are currently used in the clinic to treat tumors, and new small-molecule inhibitors are under clinical development. Therefore, we compared the effects of Cdc20 ablation with microtubule stabilizing (taxol) or destabilizing (vincristine) agents or with two mitotic drugs currently in clinical trials: BI2536 (a Plk1 inhibitor) and monastrol (an inhibitor of the kinesin Eg5). Tumoral Cdc20(lox/lox); RERT(+/Cre); H-ras-E1A cells co-expressing a histone H2B-GFP reporter were treated with 4-OHT (to disrupt Cdc20) or with the indicated drugs, and their fate was followed by videomicroscopy during 3 days. Control cells (treated with DMSO) typically undergo 3-4 cell divisions, whereas genetic ablation of Cdc20 results in metaphase arrest. All Cdc20-deficient cells undergo apoptosis from this mitotic arrest with an average latency of 20 ± 11 hr, as detected by videomicroscopy and Annexin-V staining ( Figure 6A ; Figure S4 ). Interestingly, this dramatic effect is not achieved by any of the administrated mitotic drugs. Whereas a few cells die in mitosis or interphase (red and green lines in Figure 6A ), most cells treated with these chemicals are alive and undergo several rounds of mitotic entry and exit. In fact, whereas Cdc20 ablation kills 50% of cells by 18 hr after mitotic entry, none of the drugs reaches these levels of lethality during the 72 hr recorded in this assay ( Figures 6A and 6B ). In addition, about 50% of cells treated with mitotic drugs incorporate the nucleotide analog EdU when added 24 hr after the mitotic inhibitors. This figure is reduced to less than 10% in Cdc20(lox/lox); RERT(+/Cre) cells after 4-OHT treatment (Figure S4 ). This background is probably due to cells in which 4-OHT was not active or in which the remaining amount of Cdc20 was enough for mitotic exit. In fact all these cells arrest in metaphase in the following cycle as observed by videomicroscopy (data not shown). DNA replication in cells treated with mitotic drugs results in increased ploidy that is not observed in Cdc20 null cells ( Figure S4 ). Given the relevance of mitotic poisons in the clinic, we also compared the therapeutic effect of Cdc20 ablation versus standard treatments with taxol, vincristine, or the Plk1 inhibitor BI2536. Cdc20(lox/lox); RERT(+/Cre); H-ras; E1A cells were injected into SCID mice as described above, and 4-OHT or the indicated drugs were injected i.p. 11 days after the xenotransplant (tumor size $200 mm 3 ). These treatments were repeated three times a week. In these conditions, control tumors grow exponentially, whereas genetic ablation of Cdc20 results in complete tumor regression in about 10 days. In comparison, treatment with taxol, vincristine, and BI2536 only induces partial responses ( Figure 6C ). In agreement with the data observed in vitro, immunohistochemical analysis of samples taken 3 days after the first treatment indicates lack of proliferation (as measured by BrdU incorporation) and massive apoptosis in Cdc20 null cells, whereas all other samples maintain significant levels of proliferation and reduced apoptotic markers ( Figure 6D ; Figure S4 ).
Inactivation of Mastl Synergizes with Cdk1 Inhibition in Mitotic Exit Downstream of Cdc20
To gain further insights into the molecular defects caused by lack of Cdc20, primary Cdc20(lox/lox) MEFs were transduced with adenoviruses expressing either the green fluorescent protein (GFP) or the Cre recombinase. Expression of Cre, but not GFP, in confluent cells efficiently excises exon 2 resulting in the Cdc20(D) null allele, and results in the accumulation of mitotic (MPM2-positive and phospho-H3-positive) cells ( Figure S5 ). These Cdc20(D/D) cells are arrested in metaphase, whereas post-metaphase figures (anaphase, telophase, or cytokinesis) are rarely observed. Lack of Cdc20 results in a significant increase in cyclin B1 and cyclin A2 protein levels, whereas the stabilization of securin is not as evident. Mad2 and p21
Cip1 protein levels are decreased in Cdc20 null cells, suggesting that the spindle assembly checkpoint is satisfied and that p21 Cip1 may be targeted by additional proteolytic regulators ( Figure S5 ). We next tested whether the elimination of securin and cyclin B could rescue the metaphase arrest in Cdc20 null cells as previously demonstrated in yeast (Shirayama et al., 1999; Thornton and Toczyski, 2003; Wä sch and Cross, 2002) . Individual knockdown of securin or cyclin B1 by RNAi did not rescue the mitotic arrest of Cdc20 null cells (data not shown). Because mammalian cells also express other B-type cyclins that can compensate for lack of cyclin B1, we decided to test the effect of chemical inhibitors of Cdks. Cdc20-depleted cells were treated with small-molecule inhibitors of Cdks (roscovitine, purvalanol A, RO-3306, and GCP-74514A) or other kinases such as Plk1 (GW843682X) or Aurora B (ZM447439) as additional controls. In addition a general kinase inhibitor (staurosporine) with preference to AGC (PKC family) kinases was also used. Mitotic exit (as determined by loss of rounded, morphology, decondensation of chromosomes, and loss of phospho-MPM2, phospho-H3, and Cdk-dependent phosphosites) is induced by the Cdk inhibitors RO-3306 and GCP-74514A whereas two other Cdk inhibitors (roscovitine and purvalanol A) are not efficient in inducing mitotic exit in this assay ( Figure S5 ). These differences have been previously observed in human cells treated with proteasome inhibitors (Potapova et al., 2006; Skoufias et al., 2007) , and they are likely to be due to differences in specificity and potency of these drugs.
To further study the components of the mitotic exit machinery in Cdc20 null cells, we decided to use roscovitine for three reasons. First, it is a very specific inhibitor of Cdks (Bain et al., 2007) . Second, it significantly inhibits Cdk1 kinase activity, even in Cdc20 null cells that display strong Cdk1 activity (Figure S5) . Finally, it rapidly induces mitotic exit in nocodazolearrested cells ( Figures 7A and 7B ), in agreement with the requirements for Cdk1 activity to sustain the spindle assembly checkpoint in these conditions (D'Angiolella et al., 2003) . In Cdc20 null cells, neither roscovitine alone nor the combination of roscovitine and securin RNAi allows sister chromatid separation or mitotic exit, and these cells remain in metaphase Figure S4 . without separation of sister chromatids (Figures 7A-7C; Figure S5) . We also combined Cdc20 mutant alleles with Pttg1 (encoding securin) conditional alleles (Wirth et al., 2006) Figure 7D ; Figure S5 ). Roscovitine-treated Cdc20; securin null cells are arrested in metaphase with high levels of phosphorylation of Cdk substrates ( Figures 7D and 7E) , suggesting that mitotic phosphatases cannot be activated in the absence of Cdc20. The fact that 500 nM of okadaic acid (OA), a concentration known to preferentially inhibit PP2A (Felix et al., 1990; Wu et al., 2009 ), prevents mitotic exit by roscovitine in nocodazole-arrested cells ( Figures  7A and 7B) (Skoufias et al., 2007) , suggests that PP2A may participate in mammalian mitotic exit as previously suggested in Xenopus .
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Recent data obtained in Xenopus suggest that PP2A may be inactivated by the Greatwall kinase (known as Mastl in mammals, a kinase that belongs to the AGC family represented by PKC, the original target of staurosporine), thus supporting the maintenance of Cdk-dependent phosphosites and the mitotic state (Castilho et al., 2009; Vigneron et al., 2009 ). Therefore, we tested whether the elimination of Mastl could cooperate in mitotic exit in Cdc20-deficient cells. Knockdown of Mastl by RNAi (siMastl) in Cdc20(D/D); Pttg1(D/D) double-mutant MEFs induces partial defects in mitotic entry (data not shown), consistent with a recent report in human cells (Burgess et al., 2010) . However, most Cdc20 null cells eventually arrest in metaphase with high levels of phospho-Cdk substrates and without sister chromatid separation. Interestingly, Cdc20(D/D); Pttg1(D/D); Mastl RNAi cells quickly exit from mitosis after treatment with roscovitine. In these cells, Cdk substrates are dephosphorylated, and DNA decondenses generating tetraploid cells, in some cases containing micronuclei, most likely as a consequence of rapid decondensation without separation of sister chromatids ( Figures 7D and 7E ). Although this mitotic exit is abnormal because it is not accompanied by sister chromatid separation, we have utilized the term ''mitotic exit'' throughout the manuscript to indicate loss of mitotic properties (loss of rounded morphology, chromosome decondensation, loss of mitotic phospho-residues). The effect of RNAi against Mastl is specific because it can be rescued by transfecting Cdc20 null cells with a human Mastl cDNA insensitive to the RNAi oligonucleotides ( Figure 7E ). Thus, interference of Mastl expression synergizes with roscovitine in mitotic exit in Cdc20;securin-deficient cells. This cooperation is also observed in Cdc20 null cells in the presence of securin (data not shown), and it affects dephosphorylation of Cdk substrates, but not sister chromatid separation.
Mitotic Exit Requires Activation of PP2A/B55 Complexes
The combined effect of Mastl RNAi and roscovitine is suppressed by 500 nM OA, thus suggesting that PP2A acts downstream of Mastl during mammalian mitotic exit ( Figure 7D ). It has been recently proposed that B55d is the regulatory subunit of PP2A in mitotic exit in Xenopus ). Indeed, whereas downregulation of all mammalian B55 genes (B55a,b,g,d) has no major effect on metaphase-arrested cells ( Figure S6 ), it dramatically suppresses mitotic exit after combined inactivation of Cdk1 and Mastl ( Figure 8A ), suggesting that B55 proteins are the major regulatory subunits of PP2A during mitotic exit. The B55a (Ppp2r2a) and B55d (Ppp2r2d) isoforms are widely expressed in mammalian cells (including fibroblasts), whereas B55b (Ppp2r2b) and B55g (Ppp2r2c) are restricted to the nervous system (Eichhorn et al., 2009) . In fact, downregulation of B55b does not prevent mitotic exit mediated by Cdk1 inhibition and Mastl suppression in Cdc20 null cells. However, suppression of B55a prevents 60% of mitotic exit (as determined by phosphorylation of Cdk substrates), whereas B55d accounts for 40% of the phospho-Cdk-substrate signal ( Figure 8B ), indicating that both B55a and B55d participate in the PP2A functional complexes required for mitotic exit in Cdc20 null fibroblasts. RNAi against B55 is also able to prevent mitotic exit in human or murine cells arrested with proteasome inhibitors ( Figure S6 ). HeLa or B16F10 melanoma cells arrested in metaphase by MG132 do not exit from mitosis upon treatment with roscovitine, similar to other human cells (Potapova et al., 2006; Skoufias et al., 2007) . However, concomitant treatment with roscovitine and Mastl RNAi results in rapid PP2A-B55-dependent mitotic exit ( Figure S6) . Both PP1 and PP2A may participate in mitotic exit in Xenopus Wu et al., 2009 ). In this model, dephosphorylation of PP1 inhibitor-1 (Inh1) leads to its dissociation from the catalytic subunit and full PP1 activation (Wu et al., 2009 ). Therefore, we tested the effect of suppression of Inh1 in Cdc20 null cells. As shown in Figure S6 , suppression of mouse Inh1 (Ppp1r1a) by RNAi results in a partial dephosphorylation of Cdk substrates in the presence of roscovitine. Interestingly, this exit is sensitive to 500 nM OA, suggesting that PP2A acts downstream of PP1 in mitotic exit. Thus, both phosphatases are likely to play a role in mammalian mitotic exit downstream of Cdc20, although their relative roles are yet to be established.
Altogether, these data suggest that the concomitant inhibition of Cdk1 and Mastl is a general mechanism for PP2A-mediated mitotic exit downstream of Cdc20 in both mouse and human cells. Whereas all Cdc20 null cells die in mitosis (Figure 6 ), a number of interphasic Cdc20 null cells in which Cdk1 and Mastl have been inhibited display increased viability and are able to enter into DNA replication ( Figure S6) . Thus, the inhibition of these mitotic kinases could counteract the therapeutic effect of inhibiting APC/C-Cdc20 in tumor cells.
DISCUSSION
Conditional genetic elimination of Cdc20 results in complete metaphase arrest in embryonic or somatic cells in vivo. Mitotic exit is likely to be efficient with as little as 5% of cellular Cdc20 (Wolthuis et al., 2008) , giving an explanation for previous reports indicating that Cdc20 knockdown by RNAi does not result in cyclin B stabilization or mitotic arrest (Clarke, 2009) . Cdh1 is not able to compensate for the lack of Cdc20. This is not due to differences in substrate specificity because Cdh1 is also able to target securin and cyclin B for degradation. Rather, this reflects the fact that Cdc20 absence arrests cells with high Cdk1 activity, and this activity is known to inhibit Cdh1 function (Manchado et al., 2010) .
Elimination of Cdc20 also has dramatic consequences for proliferation of tumor cells, in agreement with the recent proposal that targeting mitotic exit is a better cancer therapeutic strategy than targeting other cell cycle processes (Huang et al., 2009) . Inhibiting mitotic exit is likely to also affect pRb null, p53 null, or SAC-deficient cells (Huang et al. [2009] ,and this work). The toxicity of Cdc20 ablation in proliferative cells is much stronger than any other treatment with available mitotic drugs, such as microtubule poisons (taxol or vincristine) or targeted inhibitors against Plk1 (BI2536) or the kinesin Eg5 (monastrol). Thus, the essential requirements for Cdc20 during mitosis suggest possible benefits of inhibiting APC/C function, e.g., by P-Cdk subs.
(rel. Units) Cdk-dependent phospho-residues are also quantified and normalized independently (relative to the respective control cells in the absence of Ros or OA that are arbitrarily set to ''1'') to eliminate relative differences in the loading of proteins.
(C) A model for mitotic exit induced by Cdc20 in mammals. The relevance of Pttg1/securin degradation by Cdc20 (dashed line) is not clear because it is dispensable in the presence of cyclin B, and Pttg1 levels are not significantly increased in Cdc20 null cells. Mastl is a critical node in the pathway to inactivate PP2A/B55a,d complexes.
The presence of cyclin B may inhibit mitotic exit, even upon chemical inhibition of Cdk1, e.g., by physical interaction with separase (Gorr et al., 2005) and perhaps Mastl (question mark).
generating small molecules that prevent the APC/C-Cdc20 interaction. An interesting question that arises from these observations is whether Cdc20 null cells (or tumors cells treated with APC/C inhibitors) may adapt to this situation (exiting from mitosis without dying) and what the molecular requirements are for this exit. We show here that Cdk1 and Mastl are required for Cdc20-dependent metaphase arrest and apoptosis. Inhibition of Cdk1 and Mastl strongly synergizes in mitotic exit in the absence of Cdc20 by generating tetraploid cells. Whether inhibition of Cdk1 alone by different small-molecule inhibitors is sufficient for mitotic exit in the presence of proteasome inhibitors is currently controversial, given the differences observed with different inhibitors (Potapova et al., 2009; Skoufias et al., 2007) . At the concentrations used in this work, roscovitine is highly inefficient in inducing mitotic exit in the absence of Cdc20, although it induces a rapid exit from nocodazole arrest. Similarly, knockdown of Mastl alone is not sufficient for mitotic exit in Cdc20 null cells. However, inhibition of both kinases strongly synergizes and results in a dramatic removal of Cdk-dependent phosphates and rapid PP2A-B55a,d-dependent mitotic exit. These data suggest that partial Cdk1 inhibition is likely to be insufficient to drive mitotic exit because Cdk1 substrates are already phosphorylated, and they cannot be dephosphorylated as long as Mastl remains active.
Activation of Cdc20 should lead to the inactivation of both Cdk1 and Mastl, resulting in PP2A activation ( Figure 8C ). How Mastl is inactivated downstream of Cdc20 is not clear at this moment. Mastl contains a consensus KEN box and several putative D-box domains, although we have not been able to demonstrate APC/C-mediated degradation of this kinase (Figure S6) . One possibility is that in Cdc20 null cells direct interaction between cyclin B1 and Mastl ( Figure 8C ) prevents the efficient inactivation of this protein, even upon chemical inhibition of Cdk1. This is not a novel mechanism because direct interaction between cyclin B1 and separase inhibits this protease, even if Cdk1-dependent phospho-residues have been eliminated (Boos et al., 2008; Gorr et al., 2005) . We have also observed co-immunoprecipitation of Mastl and cyclin B1 in the same protein complexes (data not shown). Because Mastl has been proposed to be modulated by Cdk1-dependent phosphorylation (Yu et al., 2006) , it is difficult to discriminate whether this represents normal phosphorylation of Mastl by cyclin B1-Cdk1 complexes or a phosphorylation-independent interaction. The fact that roscovitine is insufficient for dephosphorylation of Cdk substrates, and this is rescued by Mastl knockdown, suggests that Mastl or the putative Mastl substrates need to be dephosphorylated prior to the activation of PP2A. Suppression of the PP1 inhibitor Inh1 results in a partial exit from mitosis in the presence of roscovitine, thus suggesting that PP1 could also participate in this pathway as previously proposed in Xenopus (Wu et al., 2009) (Figure 8C ). For instance, PP1 may be responsible for the elimination of activating phosphates on Mastl or the removal of Mastl-dependent phosphates in its substrates (Castilho et al., 2009 ). In agreement with this proposal, PP1 is likely to act upstream of PP2A because the effect of Inh1 suppression is sensitive to OA. Further focused work will be necessary to compare the relative roles of these two phosphatases during mitotic exit in mammals. In Cdc20 null cells the elimination of Mastl is necessary to activate PP2A, and full mitotic exit requires both PP2A/B55a and PP2A/B55d complexes. Because B55b and B55g are not expressed in primary MEFs, these results are likely to represent the relative amount of each of these isoforms in a particular cell type.
Altogether, these results indicate that Cdc20 is an essential driver of mitotic exit in mammalian normal or tumor cells and that mitotic exit requires Mastl inhibition and the activation of PP2A-B55a,d phosphatases. Upon elimination of Cdc20, tumor cells rapidly die of apoptosis in vitro and in vivo unless Cdk1 and Mastl kinases are inhibited. This molecular pathway may have relevant implications for designing future therapeutic strategies aimed at inhibiting APC/C and for preventing adaptation to the apoptotic cell death imposed by defective mitotic exit. How to use these strategies and how to discriminate between normal and tumor cells have been recently reviewed (Gascoigne and Taylor, 2009; Rieder and Medema, 2009 ). For instance, chemical APC/C-Cdc20 inhibitors could be used as a combinatory therapy with other mitotic poisons. Partial Cdc20 inhibition may delay mitotic exit, preventing slippage of tumoral cells, which is one of the most important mechanisms of resistance in tumor treated with mitotic drugs. Other strategies to consider may be the protection of normal cells by impeding their entry into the cell cycle. For instance, prolonged fasting concomitant to the delivery of chemotherapy dramatically reduces the toxic side effects of the treatment, while maintaining its efficacy against cancer (Raffaghello et al., 2008) . Other studies suggest the use of G1 inhibitors (e.g., Cdk4/2 inhibitors) to arrest normal cells (pRb proficient) in G0/G1, thus protecting them from toxic chemotherapies. pRb null tumor cells that do not respond to these chemicals would enter into the cell cycle, thereby making them sensitive to chemotoxic treatments (Blagosklonny and Pardee, 2001 ). Thus, on one hand, partial Cdc20 inhibition may synergize with microtubule poisons, but combination with Cdk1 inhibitors should be avoided. On the other hand, strong inhibition of APC/C-Cdc20 is likely to be highly efficient in inducing apoptotic cell death, and this property should be used in therapeutic scenarios in which proliferation of normal cells is abrogated, such as after food starvation or in combination with G1-arresting agents, to selectively protect these normal cells against efficient mitotic chemotherapies.
EXPERIMENTAL PROCEDURES Generation and Characterization of Cdc20 Mutant Mice
The Cdc20 exon 2 was flanked with loxP sites as indicated in Figure S1 . The conditions for genotyping Cdc20 mutant are available from the authors upon request. Securin conditional mutants and RERT2 mice were genotyped as described (Guerra et al., 2003; Wirth et al., 2006) . Mouse depilation (Ruzankina et al., 2007) and induction of skin tumors (Sotillo et al., 2001b) were performed as reported previously. Mutant mice were fed with 4-OHT-supplemented food (Harlan Laboratories Models), injected (i.p.) as described by Perera et al. (2007) , or topically painted with 50 ml 4-OHT (5 mg/ml). All animals were maintained in a mixed 129/Sv (25%) 3 CD1 (25%) 3 C57BL/6J (50%) background. Xenographs were generated using transformed MEFs using SCID mice (Charles Rivers) essentially as described previously (Sotillo et al., 2001a) . These mice were treated with taxol (Paclitaxel, Sigma; 12 mg/kg), vincristine (Sigma; 12 mg/kg), and BI2536 (Selleck Chemicals; 35 mg/kg) following the recommended doses reported previously (Koyanagi et al., 1994; Patel et al., 2010; Steegmaier et al., 2007) . All animal protocols were approved by the ISCIII committee for animal care and research. For histological observation, dissected organs were fixed in 10% buffered formalin (Sigma) and embedded in paraffin wax. Sections of 3 or 5 mm thickness were stained with hematoxylin and eosin (H&E). Immunohistochemistry was performed using specific antibodies against the following antigens: BrdU (GE Healthcare), Ki67 (Dako), active caspase 3 (Cell Signaling Technology), cyclin B1 (Chemical International), Cdc20 (Santa Cruz Biotechnology), and CD34 (Abcam).
Cell Culture and Treatments
MEFs were isolated from E13.5 embryos and cultured essentially as described previously (Garcia-Higuera et al., 2008) . Adenoviruses expressing GFP or Cre (supplied by the Iowa University) and siRNAs against specific transcripts (Dharmacon) were used following the manufacturer's recommendations. Briefly, adenoviruses were transduced in confluency, and cells were split 48 hr after and transfected with siRNAs when required. The following drugs were used in cultured cells at the indicated concentrations: nocodazole (Sigma; 100 ng/ml); roscovitine (Sigma; 1-200 mM; see figure legends); purvalanol A (Calbiochem; 10-100 mM); RO-3306 (Calbiochem; 10-100 mM); GCP-74514A (Calbiochem; 10-100 mM); Staurosporine (Sigma; 0.1, 1, and 10 mM); Plk1 inhibitors GW843682X (Tocris; 10-100 mM) and BI2536 (Selleck Chemicals; 100 nM); Aurora B inhibitor ZM447439 (Tocris; 10-100 mM); taxol (Sigma; 200 nM); and vincristine (Sigma; 1 mM) and monastrol (Sigma; 100 mM). The concentration of taxol, vincristine, BI2536, and monastrol was selected after testing the minimum saturating concentration required to induce mitotic arrest in MEFs. MEFs were transformed with H-ras and E1A oncogenes essentially as reported previously (Quereda et al., 2007) , and xenographs were generated by subcutaneous injection of 5 3 10 5 cells in SCID mice. For videomicroscopy, H2B-GFP expressing cells were recorded using a Deltavision Apparatus (Applied Precision) using 10 min frames during 72 hr.
Metaphase Spreads
Cells were hypotonically swollen in 40% full medium/60% tap water for 5.5 min. Hipotonic treatment is stopped by adding an equal volume of Carnoy's solution (75% pure methanol, 25% glacial acetic acid), cells are then spun down and resuspended and fixed with Carnoy's solution for 10 min. After fixation cells are dropped from a 5 cm height onto glass slides. Slides are stained with 5% Giemsa in PBS for 7 min.
Immunofluorescence and Biochemical Analysis Embryos were fixed with cold methanol during 1 hr at À20 C, rinsed with M2 medium, washed in PBS containing 0.1% BSA (Sigma), and incubated with 0.1% Triton X for permeabilization. Embryos were then blocked with 3% BSA and incubated with primary antibodies (see below) for 2-4 hr at 37 C.
The matching secondary antibodies (Alexa 488, 594, or 647) are from Molecular Probes (Invitrogen). Images were obtained using a confocal ultra-spectral microscope (Leica TCS-SP5-AOBS-UV). Cultured cells were grown in coverslips, fixed with 4% paraformaldehyde in PBS for 7 min at 37 C, permeabilized with PBS-Triton 0.15% for 2 min at 37 C, and blocked with 1% BSA for 1 hr.
Immunofluorescence in embryos or cultured cells was performed using specific antibodies against the following proteins: phospho-histone H3 (Millipore), a-tubulin (Sigma), and ACA (Antibodies Incorporated). For Western blotting, cells were harvested and lysed in RIPA buffer, and 50 mg of total protein was separated by SDS-PAGE and probed with antibodies against securin (Abcam), Cdc20 (Santa Cruz), phosphoSer-CDKs substrates (Cell Signaling Technology), cyclin B1 (Chemicon International), MASTL (Abcam), Inhibitor 1 (Ppp1r1a) (Abcam), B55 (Santa Cruz), alpha-tubulin (Sigma), phosphoHistone 3 (Millipore), cyclin A2 (Santa Cruz), Mad2 (MBL), p21 Cip1 (Santa Cruz), and a-Actin and a-tubulin (Sigma).
Statistical Analysis
Statistical analysis was performed using Student's t, chi-square, or log-rank tests (GraphPad Prism 5). All data are shown as mean ± SD; probabilities of p < 0.05 were considered significant.
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